Andersson Jan
Division of Infectious Diseases and Centre for Infectious Medicine, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
Herpes. 2006 May;13(1):12-6.
Hodgkin's lymphoma (HL) is a lymphoproliferative disorder of B-lymphocytes. Epstein-Barr virus (EBV) antigens can be detected in tumours in up to 40% of all HL cases. Patients with EBV-associated HL also show increased levels of EBV-infected B-lymphocytes in blood compared with normal individuals and non-EBV-associated HL cases. A peculiar pattern of restricted EBV-antigen expression, dominated by latent membrane protein-1 (LMP-1), LMP-2 and EBV nuclear antigen-1, is the characteristic feature of tumour-specific Hodgkin/Reed-Sternberg cells. This knowledge has generated studies examining adoptive immunotherapy of autologous or allogeneic cytotoxic T-cells for the treatment of refractory EBV-positive HL cases. Whether aborted EBV or another infectious aetiology is involved in non-EBV-associated HL cases remains an open question.
霍奇金淋巴瘤（HL）是一种B淋巴细胞的淋巴增殖性疾病。在所有HL病例中，高达40%的肿瘤中可检测到爱泼斯坦-巴尔病毒（EBV）抗原。与正常个体和非EBV相关的HL病例相比，EBV相关HL患者血液中EBV感染的B淋巴细胞水平也有所升高。以潜伏膜蛋白-1（LMP-1）、LMP-2和EBV核抗原-1为主的EBV抗原受限表达的特殊模式，是肿瘤特异性霍奇金/里德-斯腾伯格细胞的特征。这一认识催生了一些研究，探讨采用自体或同种异体细胞毒性T细胞进行过继性免疫疗法治疗难治性EBV阳性HL病例。非EBV相关HL病例是否涉及EBV感染中止或其他感染病因仍是一个悬而未决的问题。
